ArticleWorld journal of urology2025
Unicorns transforming the practice of urology: value creation and allocation in the digital age.
Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo analyze what kind of products and services unicorns, which create a substantial financial value, provide in urology and what this means for the future of urological practice. So far, the added value of unicorns has hardly been utilised for medical research, although a fraction of it would be enough to multiply the funds for urological research.
methodsAll medical unicorns (as by end of 2024) were studied, and urological unicorns identified. Publicly available data on valuation, investors, business operations and geographic distribution were analyzed to determine entrepreneurial purpose and value creation in urology.
resultsAmong the 21 unicorns in urology, the majority operate in drug research, including artificial intelligence guided development; this is in line with the digital transformation of medicine. Yet, business models are diversified. The valuations range from $ bn 1.0 to 7.83, summing to a total value of $ bn 56.2. The overwhelming majority (90%) is based in the US, one in China and one in UK.
conclusionUnicorns in urology have accumulated substantial financial impact, which may accelerate medical progress but also creates risks (such as creating inequity). These developments will likely impact the practice of urology and deserve more scientific research to inform medical societies and policy decision making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.